OVERALL RESPONSE RATE FOR ADULTS WITH PREVIOUSLY TREATED cGVHD

Responses observed based on the nationally established NIH criteria1

2 out of 3 patients achieved a PR (19/42) or CR (9/42)1

  • Responses were assessed by investigators using the 2005 NIH Consensus Panel Response Criteria with two modifications to align with the updated 2014 NIH Consensus Panel Response Criteria2

Primary endpoint: Overall Response Rate1,3,4

Time to response1

  • The median time to response coinciding with the first scheduled response assessment was 12.3 weeks (range, 4.1 to 42.1 weeks)

cGVHD=chronic graft versus host disease, CI=confidence interval, CR=complete response, NIH=National Institutes of Health, PR=partial response.

References: 1IMBRUVICA® (ibrutinib) Prescribing Information. 2Miklos D, Cutler CS, Arora M, et al. Ibrutinib for chronic graft-versus-host disease after failure of prior therapy. Blood. 2017;130(21):2243-2250. 3Pavletic SZ, Martin P, Lee SJ, et al. Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report. Biol Blood Marrow Transplant. 2006;12(3):252-266. 4Data on file.